Skip to main content
Grafa
Health
Prescient Therapeutics reaches clinical trial milestone
Image for illustrative purposes only. Not a real photo.

Prescient Therapeutics reaches clinical trial milestone

Share
  • Prescient Therapeutics enrolled 20 evaluable patients in its Phase 2a clinical trial, hitting a required dose optimisation milestone.
  • Following the announcement, the Prescient Therapeutics share price was unchanged at $0.068.
  • The company aims to review safety and efficacy data in December to guide future drug development.

Prescient Therapeutics (ASX:PTX) reached its pre-specified enrolment threshold of 20 evaluable patients for the Phase 2a trial of its oncology drug PTX-100.

The milestone triggers the trial's first planned Dose Optimisation Committee review, which remains on track to convene in December 2026.

“Reaching this first dose optimisation committee meeting reflects strong execution by our clinical team and the sites supporting this study,” said Prescient Therapeutics CEO James McDonnell.

The ongoing study includes 10 evaluable patients across two dosing arms and continues international recruitment towards a final target of 40 evaluable patients.

Following the announcement, the Prescient Therapeutics share price was unchanged at $0.068.

The biotech company focuses on developing targeted therapies for difficult-to-treat cancers.

PTX-100 has received Orphan Drug Designation and Fast Track Designation from the US FDA for specific T-cell lymphomas.

Frequently asked questions